Description

Teriseba Insulin Pen 1’ct Imported India is likely a misspelling or incorrect name for Tresiba Insulin Degludec Flex Touch Pen, a long-acting insulin product used to treat diabetes. The correct name is Tresiba, not Teriseba.Tresiba Insulin Degludec Flex Touch Pen is available in a 1’ct (1 count) package and is imported into India. It is a long-acting basal insulin that helps control blood sugar levels in adults with diabetes.The Tresiba FlexTouch pen is compatible with most universal fit needles, and NovoFine Plus 32G Tip needles are recommended as they are one of the shortest and thinnest available. The pen delivers accurate doses up to 160 units in 1 unit increments and contains 600 total units.Tresiba should be injected subcutaneously once daily at the same time each day. Injection sites should be rotated to prevent lipodystrophy. Opened pens can be used for up to 4 weeks at room temperature, while unopened pens should be refrigerated

Ultra-Long-Acting Insulin

• Tresiba is an ultra-long-acting basal insulin that provides up to 42 hours of consistent blood sugar control with a single daily injection.
• This extended duration of action helps provide stable and predictable blood glucose levels throughout the day and night.

Flexible Dosing

• The Tresiba FlexTouch pen allows for flexible once-daily dosing at any time of day that is most convenient for the patient.
• Doses can be adjusted in 1 unit increments up to 160 units per injection, providing precise dosing control.

Needle-Free Injection

• The FlexTouch pen uses a spring-loaded mechanism to deliver insulin with minimal force, allowing for a virtually painless injection experience.
• The pen also has a large, easy-to-read dose window for clear visibility of the set dose.

Durability and Convenience

• Tresiba insulin pens can be used for up to 8 weeks after first use, reducing the need for frequent pen replacements.
• The pens are also designed to be more durable, with a reinforced outer shell to withstand drops and bumps.

Reduced Hypoglycemia Risk

• Clinical studies have shown that Tresiba has a lower risk of overall, nocturnal, and severe hypoglycemia compared to other basal insulins.
• This can provide greater peace of mind and improved glycemic control for patients.
  

  Key Benefits

  • Ultra-long-acting insulin that provides up to 42 hours of consistent blood sugar control with a single daily injection 
  • Flexible once-daily dosing at any time that is convenient for the patient 
  • Precise dosing control with adjustments in 1 unit increments up to 160 units per injection 
  • Virtually painless injection experience due to the spring-loaded, needle-free delivery mechanism 
  • Durable pen design that can be used for up to 8 weeks after first use 
  • Lower risk of overall, nocturnal, and severe hypoglycemia compared to other basal insulins 

  Key Ingredient

  • The active ingredient in Tresiba is insulin degludec, a long-acting basal insulin that helps control blood sugar levels in adults with diabetes 

  Overall, the Tresiba Insulin Degludec Flex Touch Pen offers a unique combination of ultra-long-acting efficacy, flexible dosing, and improved injection experience that can benefit many patients with diabetes.                                                                                                                The mechanism of action of Tresiba (insulin degludec) is as follows:Tresiba is a long-acting basal insulin that lowers blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and adipose tissue. It also reduces hepatic glucose production.The unique molecular design of insulin degludec allows it to form soluble multi-hexamers upon subcutaneous injection, creating a depot from which insulin is slowly and continuously released, resulting in a flat and stable glucose-lowering effect with a duration of action beyond 24 hours.Specifically, after injection, the insulin degludec molecules form dihexamers in the presence of zinc and phenol. When injected into the subcutaneous tissue, the phenol diffuses away, allowing the dihexamers to form long multi-hexameric chains. Zinc then slowly diffuses away, releasing insulin monomers from the ends of the chains. This results in a stable and continuous delivery of insulin into the circulation over 24 hours or more.

Insulin degludec

Ultralong-acting basal insulin analogue

More

Developer

Developed by Novo Nordisk under the brand name Tresiba

Action Duration

Lasts up to 42 hours, making it a once-daily basal insulin

Administration

Administered via subcutaneous injection to control blood sugar level in diabetics